Since AdverseEvents Explorer has been updated with 57,000 new unreleased FAERS reports generated from our Freedom of Information Act (FOIA) requests, AEI's sales team and account managers have been seeing a lot of client activity and questions around the new anticoagulant drugs. The general sentiment appears to be that given the similar efficacy profiles, payers and providers alike are taking a “wait-and-see” approach to determine how Eliquis’ (apixaban) post-approval safety profile stacks up to that of Xarelto’s (rivaroxaban) and Pradaxa’s (dabigaran).

To help AEI's clients make more informed decisions around these drugs (as well as the antiplatelet class), we used the AdverseEvents Explorer platform to analyze the FDA data (that only we had access to) in order to examine their comparative and relative safety.

Read the full report for the details, the top-line summary is that Eliquis has the best post-approval safety profile, beating out both Xarelto and Pradaxa.

As FiercePharma nicely put it, “AdverseEvents applies logic, math and software to the database [FAERS] in an attempt to sift out the important data.”

 

Article: Eliquis earns best safety score in its class in analysis of FDA adverse event reports


Logic. Math. Software. These are three words that are almost never used together when talking about drug safety! Math... maybe. Software… rarely. Logic... WHAT?!?

That’s right. Logic.

In our day and age, data is no longer siloed off in a mysterious black pool. Healthcare decision makers can now take big data sets such as FAERS and with the right math, with the right software, logically use that data to make informed decisions.

 



Jim Davis

Jim Davis

Executive Vice President

Jim Davis LinkedinJim Davis Twitter

 

Topics: Drug Safety, FAERS

Jim Davis

Written by Jim Davis

As Executive Vice President, Jim is responsible for the commercialization strategy for Advera Health Analytics.